GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-09-19|

EQRx, CStone’s Low-Cost anti-PD-L1 Inhibitor Flaunts Encouraging Data in Stage 3 NSCLC

by Rajaneesh K. Gopinath
Share To
Lung cancer is the leading cause of cancer deaths worldwide (18.0% of the total cancer deaths). Among them, Non-small cell lung cancer (NSCLC) accounts for approximately 84% of all lung cancers. Out of the 220,000 people diagnosed with NSCLC in the US each year, about one-third of them are in stage 3, i.e., when cancer has spread to nearby lymph nodes or other parts of the body near the lungs.

In February 2018, the FDA approved AstraZeneca's Imfinzi for treating patients with unresectable stage 3 NSCLC, without disease progression after treatment with CRT after the PD-L1 inhibitor significantly improved PFS and OS in patients. This led to Imfinzi becoming the standard of care in that setting and also helped AstraZeneca dominate the stage 3 market.

At the 2021 ESMO Annual Meeting, EQRx and its partner CStone Pharmaceuticals announced positive Phase 3 trial results for a low-cost anti-PD-L1 monoclonal antibody, sugemalimab, in what could be considered a potential warning to Imfinzi. Interim analysis of trial results showed that as compared to placebo, sugemalimab demonstrated a statistically significant and clinically meaningful improvement in PFS with a well-tolerated safety profile in patients with locally advanced/unresectable Stage 3 NSCLC.

GO Prime with only $1.49 now

LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top